A practical and high throughput immunome can characterize the entire set of antigens or epitopes docked to the host immune system. This systems biology approach aims to examine the totality of the humoral immune response to infectious diseases, attempting to be as complete and accurate as possible. CD Genomics provide professional target identification services through an immunomics approach to promote our clients' project.
Over the past decade, significant advances have been made in immunomics for the development of new drugs and vaccines. Immunomics has helped us understand the host's response to foreign antigens and has laid the foundation for drug and vaccine development. Their most important challenge is to discover effective key antigens from the protein arrays encoded by the pathogen genome.
Immunomics techniques provide considerable insight into the tumor microenvironment and the tumor immune interface, facilitating both of these goals. Firstly, prospective biomarkers can be identified by bioinformatics algorithms and single-cell techniques. Secondly, neo-antigen prediction and validation enable the identification of effective targets for the adoption of cellular therapies and cancer vaccines.
Fig.1 The historical trajectory and future prospects of tumor immunomics. (Xu, Y., et al., 2021)
Rapid advances in molecular biology have fundamentally linked genomics to proteomics, which has led to the field of immunomics research.
CD Genomics offers traditional proteomics methods to provide immunoreactivity to target antigens. The combination of these conventional methods and innovative high-throughput (HTP) protein microarray technology based on immunomics provides customized solutions for target identification and epitope validation services.
CD Genomics provides two types of epitope validation services and one epitope mapping service that help clients successfully discover potential epitopes, eliminate false positive or negative results, confirm the binding affinity of candidate peptides, and facilitate appropriate prioritization based on the maximum potential of these potential epitopes.
We help our clients identify the validity of screening results and prioritize potential epitopes. We successfully eliminate false positive or negative screening results for our clients to reduce the risk of using non-target proteins for cancer or infectious disease applications.
Our epitope validation assays do what prediction tools cannot do. We confirm the physical binding properties of the actual peptide, detect the binding strength of predicted peptides, and prioritize them appropriately to eliminate false positives generated by computer algorithms.
Based on highly sensitive arrays, CD Genomics provides you with accurate, clear, and directly applicable epitope mapping services that can accurately and economically define linear, conformational, and discontinuous epitopes to promote your project.
CD Genomics provides immunomics services to our clients, and these research techniques can be used for antigen discovery. With the incorporation of high-quality data from proteomics, immunomics aims to provide an understanding of immune function. Please contact us for more information.
